PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1447590
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1447590
Liver Disease Diagnostics Market Size - By Disease Type (Hepatitis, Cirrhosis, Liver Cancer, Non-Alcoholic Fatty Liver Disease (NAFLD)), Technique (Imaging, Liver Biopsy, Endoscopy, Lab Test), End-use - Global Forecast (2024 - 2032)
Global Liver Disease Diagnostics Market is expected to register a CAGR of 7.3% between 2024-2032, fueled by technological advancements, rising prevalence of liver diseases, and increasing awareness about early diagnosis.
According to WHO, globally, 354 million individuals are affected by hepatitis B or C infections. Factors such as sedentary lifestyles, unhealthy dietary habits, and the prevalence of alcohol consumption are contributing to the rise in liver diseases, thereby increasing the demand for advanced diagnostic solutions. Moreover, the aging population, particularly in developed regions, is more susceptible to liver-related ailments. Additionally, the emphasis on early detection and intervention to prevent severe complications is fostering the adoption of liver disease diagnostic tests and procedures.
The overall liver disease diagnostics industry is classified based on disease type, technique, end-use, and region.
The liver cancer segment is poised to grow substantially till 2032, owing to the high mortality rate and limited treatment options, especially in advanced stages. Consequently, there is a pressing need for accurate and timely diagnosis of liver cancer. There are various diagnostic modalities such as imaging techniques (CT scan, MRI), blood tests (AFP, AFP-L3), and biopsy procedures. Continuous advancements in imaging technologies and biomarker identification are also enhancing the precision and reliability of liver cancer diagnosis, further propelling industry growth.
The endoscopy technique segment is anticipated to expand rapidly through 2032, offering direct visualization and tissue sampling capabilities. The evolution of endoscopic imaging technologies, including high-definition scopes and advanced imaging modalities such as narrow-band imaging (NBI) and confocal laser endomicroscopy (CLE), is revolutionizing liver disease diagnosis by providing detailed insights into tissue morphology and vascularity, propelling segment growth.
Europe liver disease diagnostics market will have lucrative opportunities during the forecast period, owing to factors such as the high prevalence of liver diseases, well-established healthcare infrastructure, and proactive government initiatives aimed at combating liver-related morbidity and mortality. The presence of key players and research institutions focused on liver health further augments the growth prospects in the region. Additionally, the rising geriatric population and increasing awareness about the importance of early diagnosis are driving the demand for liver disease diagnostic tests and procedures across Europe.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definition
- 1.2 Base estimates & calculations
- 1.3 Data collection
- 1.4 Forecast calculations
- 1.5 Data validation
- 1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
- 1.6.2.1 Paid sources
- 1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increase in prevalence of liver diseases
- 3.2.1.2 Rise in smoking, alcohol and drug consumption
- 3.2.1.3 Technological advancements in diagnostic kits
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost of diagnostic tests
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Reimbursemnt scenario
- 3.6 Future market trends
- 3.7 Technological landscape
- 3.8 Porter's analysis
- 3.8.1 Supplier power
- 3.8.2 Buyer power
- 3.8.3 Threat of new entrants
- 3.8.4 Threat of substitutes
- 3.8.5 Industry rivalry
- 3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Disease Type, 2018 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Hepatitis
- 5.3 Cirrhosis
- 5.4 Liver cancer
- 5.5 Non-alcoholic fatty liver disease (NAFLD)
- 5.6 Other disease types
Chapter 6 Market Estimates and Forecast, By Technique, 2018 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Imaging
- 6.3 Liver biopsy
- 6.4 Endoscopy
- 6.5 Laboratory tests
Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Laboratories
- 7.4 Other end-users
Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 Abbott Laboratories
- 9.2 BioMerieux SA
- 9.3 Bio-Rad Laboratories Inc.
- 9.4 Cosara Diagnostics Pvt Ltd.
- 9.5 F. Hoffmann-La Roche Ltd.
- 9.6 HORIBA Medical
- 9.7 Laboratory Corporation of America Holdings
- 9.8 Meril Life Sciences Pvt. Ltd.
- 9.9 Qiagen N.V.
- 9.10 Siemens Healthcare GmbH
- 9.11 Thermo Fisher Scientific Inc.
